| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910463038703321 |
|
|
Titolo |
Cytomegaloviruses . Volume II : from molecular pathogenesis to intervention / / edited by Matthias J. Reddehase ; with the assistance of Niels A.W. Lemmermann |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Norfolk, England : , : Caister Academic Press, , [2013] |
|
©2013 |
|
|
|
|
|
|
|
|
|
ISBN |
|
1-912530-37-6 |
1-908230-85-1 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (559 p.) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Cytomegalovirus infections |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and indexes. |
|
|
|
|
|
|
Nota di contenuto |
|
Contents Volume II; Abbreviations used in Volume II; Ch II.1: Synopsis of Clinical Aspects of Human Cytomegalovirus Disease; Ch II.2: The Epidemiology and Public Health Impact of Congenital Cytomegalovirus Infection; Ch II.2 - Addendum: The Economic Impact of Congenital CMV Infection: Methods and Estimates; Ch II. 3: Clinical Cytomegalovirus Research: Congenital Infection; Ch II. 4: Cytomegalovirus Replication in the II.4Developing Human Placenta; Ch II.5: The Guinea Pig Model of Congenital Cytomegalovirus Infection; Ch II. 6: Murine Model of Neonatal Cytomegalovirus Infection |
Ch II.7: Adaptive Cellular Immunity to Human II.7CytomegalovirusCh II.8: Natural Killers Cells and Human Cytomegalovirus; Ch II.9: Innate Immunity to Cytomegalovirus in the Murine Model; Ch II.10: Protective Humoral Immunity; Ch II.11: Immunoregulatory Cytokine Networks Discovered and Characterized during Murine Cytomegalovirus Infections; Ch II.12: Host Genetic Models in Cytomegalovirus Immunology; Ch II.13: Clinical Cytomegalovirus Research: Thoracic Organ Transplantation; Ch II.14: Clinical Cytomegalovirus Research: Liver and Kidney Transplantation |
Ch II.15: The Rat Model of Cytomegalovirus Infection and Vascular DiseaseCh II.16: Clinical Cytomegalovirus Research: Haematopoietic |
|
|
|
|
|
|
|
|
|
|
|
Cell Transplantation; Ch II.17: Murine Model for Cytoimmunotherapy of CMV Disease after Haematopoietic Cell Transplantation; Ch II.18: State of the Art and Trends in Cytomegalovirus Diagnostics; Ch II.19: Antiviral Therapy, Drug Resistance and Computed Resistance Profiling; Ch II 20: Cytomegalovirus Vaccine: On the Way to the Future?; Ch II.21: Vaccine Vectors Using the Unique Biology and Immunology of Cytomegalovirus |
Ch II.22: Non-Human-Primate Models of Cytomegalovirus Infection, Prevention, and TherapyCh II. 23: Putative Disease Associations with Cytomegalovirus: a Critical Survey; Epilogue - Résumé and Visions: From CMV Todayto CMV Tomorrow; Subject index; Open reading frame index; Cluster of differentiation index; CMV strains index; Antiviral drugs index; Frequently discussed molecules |
|
|
|
|
|
|
Sommario/riassunto |
|
Human Cytomegalovirus (CMV) - a member of the herpesvirus family - is an underrated health risk. A low public awareness results from the relatively mild symptoms it causes in otherwise healthy people whose immune systems are intact, with primary infection usually going unnoticed. During pregnancy, however, transmission from the mother to the fetus is currently the most frequent viral cause of birth defects with lifelong neurological sequelae, sensorineural hearing loss in particular. People at risk also include the growing number of immune compromised patients requiring either a solid organ gr |
|
|
|
|
|
|
|
| |